Attached files
file | filename |
---|---|
EX-32.2 - EX-32.2 - BIOLASE, INC | biol-ex322_7.htm |
EX-31.2 - EX-31.2 - BIOLASE, INC | biol-ex312_6.htm |
EX-31.1 - EX-31.1 - BIOLASE, INC | biol-ex311_8.htm |
EX-32.1 - EX-32.1 - BIOLASE, INC | biol-ex321_10.htm |
EX-10.2 - EX-10.2 - BIOLASE, INC | biol-ex102_488.htm |
10-Q - 10-Q - BIOLASE, INC | biol-10q_20150630.htm |
Exhibit 10.3
Biolase, Inc.
4 Cromwell
Irvine, California 92618
Jeffrey M. Nugent
c/o Biolase, Inc.
4 Cromwell
Irvine, California 92618
Re: |
Transition Arrangement |
Dear Jeff:
The purpose of this letter is to confirm the circumstances of your employment as President and Chief Executive Office of Biolase, Inc. (the “Company”), as we have discussed recently. Our intent is to facilitate the Company’s transition to a new President and Chief Executive Officer and to provide you with a monetary payment (the “Transition Payment”), in exchange for your efforts to stabilize the Company’s Waterlase product line sales and improve overall product quality, as well as for your help and assistance in this transition.
We plan to continue your employment as President and Chief Executive Officer at your current base salary and benefits, through and including the day before the start date of the new President and Chief Executive Officer (the “Final Transition Date”), which is expected to be on or before July 13, 2015. During that period of time, we expect that you will devote your full business time and best efforts to the Company, although you may be transitioning your duties and responsibilities to others, as advised by the Chairman of the Board of Directors. Although our plan is to continue your employment through the Final Transition Date, your employment status until that time will remain “at will,” which means that either you or the Company may end your employment at any time for any reason.
Provided that you remain employed by the Company on the Final Transition Date, and you have performed your transitional duties to the Board’s reasonable satisfaction, and provided on the Final Transition Date you cease to act in any capacity (including as an officer or director) for the Company, the Company agrees to (i) provide you with a Transition Payment equal to $150,000.00, payable in six (6) equal consecutive monthly installments in accordance with the Company’s normal payroll cycle and less all normal payroll deductions, (ii) continue the time-based vesting of your stock option grant and the time-based vesting of your restricted stock unit award, with such awards to become exercisable or settled, as applicable, in accordance with the original vesting dates set forth in the underlying award agreements, (iii) extend the period to exercise your vested stock options until the expiration date of such options, and (iv) subject to your timely election of COBRA continuation coverage, reimburse you for COBRA premiums for you (and your eligible dependents) under the Company’s medical and dental benefit plans in which you participated in as of the Final Transition Date, for up to the full the eighteen (18) month period following the Final Transition Date. The foregoing benefits shall be subject to your execution and non-revocation of the attached Separation Agreement with Release of All Claims within the time-period specified in such agreement.
If your employment ends for any reason before the Final Transition Date (unless by mutual agreement between you and the Company), you will not be eligible for the Transition Payment or the other benefits described in this letter.
Please sign below to indicate your acceptance of this agreement.
We thank you, Jeff, for your hard work, dedication, and contribution to the Company, and we look forward to a mutually beneficial transition.
/s/ Paul N. Clark |
|
Paul N. Clark |
Chairman |
ACCEPTED AND AGREED:
/s/ Jeffrey M. Nugent |
|
Dated: May 14, 2015 |
Jeffrey M. Nugent |
|
|
2
SEPARATION AGREEMENT WITH GENERAL RELEASE OF ALL CLAIMS
This Separation Agreement With General Release of All Claims (“Agreement”) is entered into by and between Jeffrey M. Nugent (“Mr. Nugent”), and Biolase, Inc., a Delaware corporation (the “Company”), and is intended by the parties hereto to settle fully and finally any claims that Mr. Nugent may have against the Company and all obligations of the Company to Mr. Nugent, except as set forth in and incorporated into this Agreement.
a. |
Employment Separation. Mr. Nugent’s employment with the Company ended effective July ___, 2015 (the “Separation Date”). From and after the Separation Date, Mr. Nugent shall no longer be employed by, or act in any capacity (including as a director) for, the Company, and Mr. Nugent’s membership on all Company boards and committees ceased as of the Separation Date. |
b. |
Termination Pay. Mr. Nugent acknowledges that he has been paid his base salary and accrued but unused vacation through the Separation Date (“Termination Pay”). Mr. Nugent shall submit expense reimbursement requests with suitable documentation within thirty (30) days following the Separation Date, and the Company shall promptly process such requests in accordance with its expense reimbursement policies. |
c. |
Payments; Extension of Vesting and Exercise Periods; COBRA Premiums. In consideration for the promises contained herein and subject to Mr. Nugent’s continued compliance with the terms and conditions of this Agreement and his execution and non-revocation of this Agreement within the timeframe specified herein, Mr. Nugent shall receive the following benefits: |
i. |
Compensation equal to $150,000.00, less all applicable withholding and deductions. The foregoing compensation shall be payable in equal monthly installments commencing on the first day of the month following the non-revocation and expiration of the seven (7) day revocation period identified below, and ending on the five (5) month anniversary of such date, and shall be paid in accordance with the Company’s standard payroll practices and procedures. |
ii. |
The period to exercise Mr. Nugent’s vested stock options shall be extended until the expiration date of such options (as specified in the underlying award agreement), and Mr. Nugent’s outstanding time-based stock option and restricted stock unit awards shall continue to become vested, or settled, as applicable, in accordance with the original vesting dates set forth in the underlying award agreements. |
iii. |
Subject to Mr. Nugent’s timely election of COBRA continuation coverage, the Company shall pay COBRA premiums for Mr. Nugent (and his eligible dependents) under the Company’s medical and dental benefit plans in which Mr. Nugent participated in as of the Separation Date, for the eighteen (18) month period following the Separation Date. |
d. |
Vested Retirement Benefits. Nothing in this Agreement shall limit, expand upon, or alter in any way any vested retirement benefits that Mr. Nugent has or is entitled to receive under any Company sponsored 401(k) or other retirement plan to which Mr. Nugent may have been entitled to participate by virtue of his employment. Mr. Nugent’s rights and obligations shall continue to be governed by the terms of such plans, as they presently exist or as they may permissibly be amended, and shall be based upon his Separation Date. |
e. |
No Other Payments. Other than whatever is specifically provided for in this Agreement, Mr. Nugent acknowledges that there are no other sums or benefits of any nature whatsoever due and owing to him, other than whatever ongoing or future payments are provided for in this Agreement. In consideration for this Agreement, Mr. Nugent specifically waives any claim that he may have to any past, present, or future compensation of any nature whatsoever arising out of his prior employment with the Company. |
3
g. |
Biolase Proprietary Information. As a material inducement to Biolase to enter into this Agreement, Mr. Nugent covenants and represents that (i) he has complied with the terms and conditions of the Biolase Proprietary Information Agreement at all times during his employment with Biolase; and (ii) he will continue to comply with such terms for the periods specified therein. The terms of the Biolase Proprietary Agreement are incorporated into this Agreement by reference and made a part hereof. |
h. |
Continuing Obligations of Mr. Nugent. To the extent that Mr. Nugent has come into contact with confidential or trade secret information concerning the Company and its operations or concerning the Company’s customers, prospective customers, or projects, Mr. Nugent will continue to protect the confidentiality of such information. In addition, Mr. Nugent represents and warrants that, he has returned to the Company and has not copied or duplicated in any manner whatsoever, all tangible and intangible property (including, without limitation, all computer hardware, whether portable or stationary, and software), books, records, documents and reports owned by, or pertaining to the business of, the Company or any of the Company’s existing or prospective clients that was in Mr. Nugent’s possession or under Mr. Nugent’s direct or indirect control as of the Separation Date. If Mr. Nugent shall come into possession of any property (tangible or intangible), books, records, documents or reports of the type described above after the Separation Date, Mr. Nugent will promptly return them to the Company. |
i. |
Complete Release. Mr. Nugent, on behalf of himself, his heirs and assigns, fully and forever releases and discharges the Company and, as the case may be, each of its respective employees, shareholders, officers, directors, agents, attorneys, predecessors, successors, assigns, and affiliated corporations or organizations, whether previously or hereafter affiliated in any manner (collectively, the “Released Company Parties”), to the fullest extent permitted by law, from any and all claims, demands, causes of action, charges of discrimination, obligations, damages, attorneys’ fees, costs and liabilities of any nature whatsoever, including all claims of race, sex, national origin, religion, handicap and age discrimination under any federal or state statute, whether or not now known, suspected or claimed, which Mr. Nugent ever had, now has, or may claim to have as of the date of this Agreement against the Released Company Parties. |
4
k. |
Release of Unknown Claims. It is the intention of Mr. Nugent to release both known and unknown claims of any nature whatsoever. This includes, without limitation, claims, which Mr. Nugent does not know or suspect to exist in his favor at the time of executing this release, even though such claims, if known by him would have materially affected his settlement with the Company. Accordingly, Mr. Nugent expressly waives all rights under Section 1542 of the Civil Code of the State of California, which reads as follows: |
“A general release does not extend to claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by him must have materially affected his settlement with the debtor.”
l. |
Non-Disparagement; Neutral Reference. Mr. Nugent agrees during the term of this Agreement and for a period of ten (10) years thereafter, he shall not, in any communication with any person or entity, including any actual or potential customer, client, investor, vendor, or business partner of the Company, or any third party media outlet, make any derogatory or disparaging or critical negative statements – orally, written or otherwise – against the Company, or any of its directors, officers, agents, employees, contractors, or affiliated persons or entities. Mr. Nugent also agrees that unless compelled by valid legal process he will not give or offer to provide any statements, testimony or the like in connection with any claim, action, or demand (being contemplated or) brought against the Company which concerns the Company, his employment or the cessation of his employment with the Company, the Company’s business practices, its customers and/or prospective customers, its products, and/or any other aspect of the Company’s business, its directors, officers, agents, employees, contractors, or affiliated persons or entities. Further, Mr. Nugent agrees that if he agrees that should he be called as a witness or to provide testimony in any case, action, and/or proceeding concerning the Company, he and/or his counsel will contact either the President and Chief Executive Officer or the Secretary of the Company immediately, but in no event later than ten (10) days before he is to be deposed or to testify as a witness, so that the Company can take whatever precautionary measures it deems necessary to protect from disclosure any of its proprietary and/or confidential information and/or documents. |
m. |
No Other Actions. Mr. Nugent represents and covenants that he has not filed or lodged any complaints or charges against any of the Released Company Parties with any local, state, or federal agency or court. |
5
o. |
No Future Actions. Mr. Nugent covenants and agrees never to commence, aid in any way, prosecute or cause to be commenced or prosecuted any action or other proceeding based upon any claims, demands, causes of action, obligations, damages or liabilities which are the subject of this Agreement; provided however, that Mr. Nugent does not relinquish any protected rights he may have to file a charge, testify, assist or participate in any manner in an investigation, hearing or proceeding conducted by the Equal Employment Opportunity Commission, the Office of Federal Contract Compliance, or any similar state human rights agency. However, Mr. Nugent may not recover additional compensation or damages as a result of such participation. |
p. |
Twenty-One Day Consideration Period. This Agreement was originally given to Mr. Nugent on the Separation Date. Mr. Nugent shall have twenty-one (21) days to consider this Agreement; provided however, that if Mr. Nugent chooses to sign this Agreement before the end of this twenty-one (21)-day period, Mr. Nugent acknowledges that he does so knowingly and voluntarily and waives any claim that to the effect that he was not given the full twenty-one (21) days to consider whether to sign this Agreement or did not use the entire period of time available to consider this Agreement or to consult with an attorney. |
q. |
Seven Day Revocation Period. Following execution of this Agreement, Mr. Nugent shall have seven (7) days to revoke this Agreement. To be effective, the revocation must be in writing and signed by Mr. Nugent and must be delivered to and received by the Company, before 5 p.m. of the 7th day. This Agreement shall become effective on the eighth (8th) day following the execution of this Agreement. Any revocation shall be in writing and shall be effective upon timely receipt by the Company by: Corporate Secretary, Biolase, Inc., 4 Cromwell, Irvine, California, 92618. |
r. |
Non-Assignment of Claim. Mr. Nugent warrants that he has made no assignment and will make no assignment of any claim, chose in action, right of action, or any right of any kind whatsoever, embodied in this Agreement and referred to herein, and that no other person or entity of any kind (other than as expressly mentioned above) had or has any interest in any of the demands, obligations, actions, causes of action, debts, liabilities, rights, contracts, damages, attorneys’ fees, costs, expenses, losses or claims referred to herein. |
s. |
Successors and Assigns. This Agreement, and all the terms and provisions hereof, shall be binding upon and shall inure to the benefit of the parties and their respective heirs, legal representatives, successors and assigns. |
t. |
Assistance of Counsel. Mr. Nugent acknowledges that he has been advised to consult with counsel of his choosing before entering into this Agreement. The parties specifically represent that they either have consulted to their satisfaction with their attorneys, or have elected on their own accord not to seek legal counsel, prior to executing this Agreement concerning the terms and conditions of this Agreement. |
u. |
Interpretation. Should any portion, word, clause, phrase, sentence or paragraph of this Agreement be declared void or unenforceable, such portion shall be considered independent and severable from the remainder, the validity of which shall remain unaffected. Whenever required by the context, as used in this Agreement the singular number shall include the plural, and the masculine gender shall include the feminine and neuter. |
v. |
Entire Agreement. This Agreement constitutes the entire agreement between the parties who have executed it and supersedes any and all other agreements, understandings, negotiations, or discussions, either oral or in writing, express or implied, between the parties to this Agreement. The parties hereto acknowledge that no representations, inducements, promises, agreements, or warranties, oral or otherwise, have been made by them, or anyone acting on their behalf, which are not embodied in this Agreement, that they have not executed this Agreement in reliance on any such representations, inducements, promise, agreement or warranty, and that no representation, inducement, promise, agreement or warranty not contained in this Agreement, including, but not limited to, any purported supplements, modifications, waivers or terminations of this Agreement shall be valid or binding, unless executed in writing by all of the parties to this Agreement. |
6
w. |
Governing Law. This Agreement shall be enforced and governed under the laws of the State of California without reference to its choice of law provisions. |
x. |
Knowing and Voluntary Agreement. This Agreement in all respects has been voluntarily and knowingly executed by the parties hereto. |
y. |
Counterparts. This Agreement may be executed in counterparts, and when each party has signed and delivered at least one such counterpart, each counterpart shall be deemed an original, and, when taken together with other signed counterparts, shall constitute one agreement, which shall be binding upon and effective as to all parties. |
z. |
No Waiver. Failure to insist on compliance of any term, covenant or condition contained in this Agreement shall not be deemed a waiver of that term, covenant, or condition, nor shall any waiver or relinquishment of any right or power contained in this Agreement at any one time or more times be deemed a waiver or relinquishment of any right or power at any other time or times. |
aa. |
Arbitration. Any disputes concerning this Agreement or otherwise arising out of this Agreement or Mr. Nugent’s employment or termination that the parties are unable to resolve among them shall be submitted to final and binding arbitration in Orange County, California at and under the rules of the Judicial Arbitration and Mediation Service (“JAMS”); provided that nothing in this provision shall prevent the Company from seeking injunctive relief in any Court of competent jurisdiction. |
bb. |
Section 409A. The payments to Mr. Nugent pursuant to this Agreement are intended to be exempt from Section 409A of the Internal Revenue Code of 1986, as amended, to the maximum extent possible, under either the separation pay exemption pursuant to Treasury regulation §1.409A-1(b)(9)(iii) or as short-term deferrals pursuant to Treasury regulation §1.409A-1(b)(4), and for such purposes, each installment paid to Mr. Nugent under this Agreement shall be considered a separate payment. In the event the terms of this Agreement would subject Mr. Nugent to taxes or penalties under Section 409A of the Code (“409A Penalties”), the Company and Mr. Nugent shall cooperate diligently to amend the terms of the Agreement to avoid such 409A Penalties, to the extent possible; provided that in no event shall the Company be responsible for any 409A Penalties that arise in connection with any amounts payable under this Agreement. |
IN WITNESS WHEREOF, the undersigned have executed this Separation Agreement and General Release of All Claims on the date(s) set forth hereinafter.
Dated: , 2015 |
|
By: |
|
|
|
|
|
|
JEFFREY M. NUGENT |
|
|
|
|
|
|
|
BIOLASE, INC. |
||
|
|
|
|
|
Dated: , 2015 |
|
By: |
|
|
|
|
|
|
Paul N. Clark |
|
|
|
|
Chairman |
7